DKM 2-93

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

DKM 2-93 是一种相对选择性的 UBA5 抑制剂 (IC50 : 430 μM)。

DKM 2-93 is a relatively selective inhibitor of UBA5(IC50 : 430 μM).

Ubiquitin-like modifier activating enzyme 5 (UBA5) is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC50s of 90 and 30 μM, respectively.

DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity.

——

Proteasome/Ubiquitin

E1

UBA5

——

——

65836-72-8

243.69

C11H14ClNO3

>98% (HPLC)

DMSO:150 mg/mL (615.54 mM)

COc1ccc(CNC(=O)CCl)cc1OC

2-Chloro-N-(34-dimethoxy-benzyl)-acetamide

(-20℃)

With Ice Pack

≥ 2 years